Dr. Brian Harvey, MD

NPI: 1285636217
Total Payments
$355,038
2024 Payments
$106,500
Companies
12
Transactions
103

Payment Breakdown by Category

Consulting$353,425 (99.5%)
Travel$1,328 (0.4%)
Food & Beverage$286.04 (0.1%)
Other$0.00 (0.0%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $353,425 95 99.5%
Travel and Lodging $1,328 4 0.4%
Food and Beverage $286.04 4 0.1%

Top Paying Companies

Company Total Records Latest Year
Beckman Coulter, Inc. $106,500 5 $0 (2024)
DiaSorin Inc. $89,550 7 $0 (2023)
Amgen Inc. $78,563 42 $0 (2018)
Organon LLC $40,300 4 $0 (2022)
E.R. Squibb & Sons, L.L.C. $19,500 28 $0 (2018)
Coherus Biosciences Inc. $8,750 3 $0 (2020)
PFIZER INC. $5,122 8 $0 (2017)
RedHill Biopharma Inc. $4,750 1 $0 (2020)
Dr.Reddy's Laboratories,Inc. $856.00 2 $0 (2017)
VERTEX PHARMACEUTICALS INCORPORATED $573.85 1 $0 (2019)

Payment History by Year

Year Amount Transactions Top Company
2024 $106,500 5 Beckman Coulter, Inc. ($106,500)
2023 $5,625 1 DiaSorin Inc. ($5,625)
2022 $48,850 5 Organon LLC ($40,300)
2021 $7,875 1 DiaSorin Inc. ($7,875)
2020 $30,600 5 DiaSorin Inc. ($17,100)
2019 $6,874 2 DiaSorin Inc. ($6,300)
2018 $75,349 33 Amgen Inc. ($40,875)
2017 $73,366 51 Amgen Inc. ($37,688)

All Payment Transactions

103 individual payment records from CMS Open Payments — Page 1 of 5

Date Company Product Nature Form Amount Type
09/27/2024 Beckman Coulter, Inc. DXI 9000 Access Immunoassay Analyzer (Device) Consulting Fee Cash or cash equivalent $17,750.00 General
Category: Devices
08/30/2024 Beckman Coulter, Inc. DXI 9000 Access Immunoassay Analyzer (Device) Consulting Fee Cash or cash equivalent $2,500.00 General
Category: Devices
07/26/2024 Beckman Coulter, Inc. DXI 9000 Access Immunoassay Analyzer (Device) Consulting Fee Cash or cash equivalent $7,750.00 General
Category: Devices
06/28/2024 Beckman Coulter, Inc. DXI 9000 Access Immunoassay Analyzer (Device) Consulting Fee Cash or cash equivalent $35,000.00 General
Category: Devices
05/31/2024 Beckman Coulter, Inc. DXI 9000 Access Immunoassay Analyzer (Device) Consulting Fee Cash or cash equivalent $43,500.00 General
Category: Devices
05/01/2023 DiaSorin Inc. Various (Device) Consulting Fee Cash or cash equivalent $5,625.00 General
Category: In-vitro diagnostics
09/16/2022 Organon LLC REMERONSOLTAB (Drug) Consulting Fee Cash or cash equivalent $3,575.00 General
Category: MIRTAZAPINE
09/07/2022 Organon LLC REMERONSOLTAB (Drug) Consulting Fee Cash or cash equivalent $14,300.00 General
Category: MIRTAZAPINE
08/19/2022 Organon LLC REMERONSOLTAB (Drug) Consulting Fee Cash or cash equivalent $10,075.00 General
Category: MIRTAZAPINE
08/15/2022 Organon LLC REMERONSOLTAB (Drug) Consulting Fee Cash or cash equivalent $12,350.00 General
Category: MIRTAZAPINE
07/01/2022 DiaSorin Inc. Various (Device) Consulting Fee Cash or cash equivalent $8,550.00 General
Category: IVD
01/01/2021 DiaSorin Inc. Consulting Fee Cash or cash equivalent $7,875.00 General
02/13/2020 Coherus Biosciences Inc. Consulting Fee Cash or cash equivalent $4,000.00 General
02/10/2020 RedHill Biopharma Inc. Consulting Fee Cash or cash equivalent $4,750.00 General
01/09/2020 DiaSorin Inc. Consulting Fee Cash or cash equivalent $17,100.00 General
01/09/2020 Coherus Biosciences Inc. Consulting Fee Cash or cash equivalent $2,750.00 General
01/09/2020 Coherus Biosciences Inc. Consulting Fee Cash or cash equivalent $2,000.00 General
06/19/2019 VERTEX PHARMACEUTICALS INCORPORATED Consulting Fee Cash or cash equivalent $573.85 General
05/02/2019 DiaSorin Inc. Consulting Fee Cash or cash equivalent $6,300.00 General
Category: More than 5 specific products
06/01/2018 Vanda Pharmaceuticals Inc. Food and Beverage In-kind items and services $91.34 General
05/04/2018 E.R. Squibb & Sons, L.L.C. Consulting Fee Cash or cash equivalent $375.00 General
04/20/2018 E.R. Squibb & Sons, L.L.C. Consulting Fee Cash or cash equivalent $1,687.50 General
04/20/2018 E.R. Squibb & Sons, L.L.C. Consulting Fee Cash or cash equivalent $1,125.00 General
04/20/2018 E.R. Squibb & Sons, L.L.C. Consulting Fee Cash or cash equivalent $750.00 General
04/06/2018 E.R. Squibb & Sons, L.L.C. Consulting Fee Cash or cash equivalent $1,125.00 General

About Dr. Brian Harvey, MD

Dr. Brian Harvey, MD is a Internal Medicine healthcare provider based in Annapolis, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/10/2005. The National Provider Identifier (NPI) number assigned to this provider is 1285636217.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Brian Harvey, MD has received a total of $355,038 in payments from pharmaceutical and medical device companies, with $106,500 received in 2024. These payments were reported across 103 transactions from 12 companies. The most common payment nature is "Consulting Fee" ($353,425).

Practice Information

  • Specialty Internal Medicine
  • Location Annapolis, MD
  • Active Since 08/10/2005
  • Last Updated 06/16/2008
  • Taxonomy Code 207R00000X
  • Entity Type Individual
  • NPI Number 1285636217

Products in Payments

  • DXI 9000 Access Immunoassay Analyzer (Device) $106,500
  • REMERONSOLTAB (Drug) $40,300
  • Various (Device) $14,175

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Internal Medicine Doctors in Annapolis